HPV Screening: Protocols and Result Interpretation
Understanding the tools used to detect cervical dysplasia and prevent progression to cancer.
For more foundational information on HPV, please start with our Pillar Guide on HPV Prevention.
Cervical cancer is one of the most preventable cancers, largely due to effective screening programs. The goal of screening is not to diagnose cancer, but to identify the precursors to cancer—cellular changes caused by persistent high-risk HPV infections—long before they become invasive.
1. The Tools of Screening: Cytology vs. Virology
There are two primary tests used in cervical cancer screening, often performed simultaneously using the same sample of cervical cells.
The Pap Smear (Cytology)
Developed in the 1940s, the Papanicolaou (Pap) test examines cells collected from the transformation zone of the cervix under a microscope. It looks for morphological abnormalities (dysplasia) indicating that the cells are undergoing changes that could lead to cancer.
- Strengths: Highly specific. If abnormal cells are seen, they are usually present.
- Limitations: Lower sensitivity. It can miss early cellular changes, requiring repeated testing over time to ensure detection.
The HPV Test (Primary Screening)
The HPV test detects the genetic material (DNA or mRNA) of the high-risk HPV types known to cause cervical cancer, such as types 16 and 18.
- Strengths: Highly sensitive. It detects the presence of the virus before cellular changes even occur. A negative HPV test provides a very high degree of reassurance that cervical cancer will not develop in the near future.
- Limitations: Lower specificity for disease. Because most HPV infections clear on their own, a positive HPV test does not necessarily mean precancer is present, often leading to anxiety and potentially unnecessary follow-up procedures (overtreatment).
Co-Testing
Co-testing involves performing both the Pap smear and the HPV test simultaneously. This approach maximizes sensitivity and provides the most comprehensive assessment of risk, though many guidelines are shifting toward primary HPV testing alone due to its high negative predictive value.
2. Standard Screening Intervals
Screening guidelines are designed to balance the benefit of detecting precancerous lesions with the harm of over-treating transient HPV infections, which are extremely common in young adults and typically resolve without intervention.
Note: The following represents generalized guidelines for average-risk individuals with a cervix. Always consult a healthcare provider for personalized advice.
- Under Age 21: Screening is generally not recommended, regardless of the age of sexual onset. The risk of cervical cancer is exceedingly low, and most HPV infections in this age group will clear naturally. Screening often leads to unnecessary procedures that can compromise future cervical competence.
- Ages 21 to 29: A Pap smear alone every 3 years is widely recommended. Routine HPV testing is usually not recommended in this age group due to the high prevalence of transient, benign infections.
- Ages 30 to 65: Three main options are supported by major medical organizations:
- Primary HPV testing every 5 years (preferred by many updated guidelines).
- Co-testing (Pap + HPV test) every 5 years.
- Pap smear alone every 3 years.
- Over Age 65: Screening can typically be discontinued if prior screening history is adequate (e.g., three consecutive negative Pap tests or two consecutive negative co-tests within the past 10 years, with the most recent test within the past 5 years) and there is no history of high-grade precancerous lesions (CIN 2 or CIN 3) in the past 25 years.
3. Understanding Your Results
If a Pap smear returns abnormal results, the findings are categorized using the Bethesda System. These classifications describe the degree of cellular abnormality.
| Classification | Meaning | Typical Follow-up |
|---|---|---|
| ASCUS (Atypical Squamous Cells of Undetermined Significance) | The most common abnormal result. Cells look slightly abnormal, but not clearly precancerous. Often caused by HPV, inflammation, or yeast. | HPV reflex testing (if not already done). If HPV+, colposcopy. If HPV-, repeat Pap in 1-3 years. |
| LSIL (Low-Grade Squamous Intraepithelial Lesion) | Mild dysplasia. Indicates a likely transient HPV infection. These changes frequently resolve on their own, especially in younger individuals. | Often observation (repeat testing in 1 year) or colposcopy, depending on age and prior results. |
| HSIL (High-Grade Squamous Intraepithelial Lesion) | Moderate to severe dysplasia. These are more significant changes with a higher risk of progressing to cancer if left untreated. | Immediate colposcopy is almost always required. Treatment (e.g., LEEP) may be indicated. |
| ASC-H (Atypical Squamous Cells, Cannot Exclude HSIL) | Cells look abnormal, and while they don't clearly look like HSIL, a high-grade lesion cannot be ruled out. | Colposcopy is required to further evaluate the cells. |
4. The Colposcopy
If screening results indicate a significant risk for high-grade dysplasia (e.g., persistent ASCUS with a positive HPV test, LSIL, or HSIL), a colposcopy is the standard next step. A colposcopy is an in-office procedure where a provider uses a lighted magnifying instrument (a colposcope) to closely examine the cervix. If abnormal areas are identified, a small biopsy may be taken for definitive histological diagnosis.
5. The Interactive Screening Recommendation Tool
Use the tool below to see general screening recommendations based on age and basic risk factors. This is for educational purposes only and does not replace medical advice.